Russia completes clinical trials of COVID-19 vaccine

Must read

Ndaman Joshua Olayinka
Tech Zealot and Passionate about writing everything concerning it. I support Arsenal.

Russia has become the first country to have successfully completed clinical trials of a Covid-19 vaccine in Sechenov First Moscow State Medical University. The research has been completed and it proved that the vaccine is safe & effective.

Gamaleya Scientific Research Institute of Epidemiology and Microbiology along with the Russian defence ministry developed and produced the covid-19 vaccine. Russian embassy in South Africa tweeted about an update on the vaccine they have been working on.

According to Forbes, Elena Smolyarchuk, chief researcher for the Russian Center for Clinical Research on Medications at Sechenov University, told TASS newswire on Sunday that human trials for the vaccine had been completed. The volunteers are to be discharged from hospital on July 15 and July 20.

TASS news agency report said the ministry had claimed that none of the volunteers reported any complaints, they experienced no side-effects, and would be discharged from the hospital soon. “Both the first and second groups were forming an immune response after injections of the vaccine.” They are going to test for the Efficiency and immunogenicity of the vaccine on the next volunteers for the trials. The clinical trials will pass through three phase.

All vaccines pass through three phases , the second and third phase could take several months. World Health Organization, Official said that “It will take at least 12-18 months before any Coronavirus vaccine is able to hit the market”. 

Globally, there are 19 COVID-19 vaccine candidates currently in clinical trials,” the WHO Africa said in a statement.

Meanwhile, Russia has confirmed 733,699 cases of coronavirus and 11,439 deaths as of July 13.

Source: Forbes

Read Also: COVID-19: Nigeria develops, launches ‘RNA SWIFT’ test kit

More articles

Leave A Reply

Please enter your comment!
Please enter your name here

Latest article